A Chinese MRNA crown vaccine that has not been approved in the country of natives has obtained the first emergency use authorization in Indonesia.
Comprehensive Reuters and the People's Daily Online reported that the Indonesian National Food and Drug Administration announced on Thursday (September 29) that the China MRNA crown disease vaccine was urgently authorized for people 18 years old and over.
This vaccine was jointly developed by the Academy of Military Medical Medicine of the Chinese Academy of Military Sciences of the Chinese People's Liberation Army, the Abo Biology and Watson Biological, which is also the first crown disease mRNA vaccine to be approved to enter the clinical trial.Official experimental data proves its defense effect on crown disease.
Penny K. Lukito, director of the Indonesian Food and Drug Administration, said the vaccine has obtained emergency use authorization and halal certification in Indonesia, which will be used for basic immunity and enhanced needle.This vaccine can be stored at 2 to 8 degrees Celsius, and it can be stored under conventional cold chain conditions. There is no need to thaw before use.
Indonesia currently uses the MRNA vaccine produced by PFIZER-BIONTECH and Modner, which has been vaccinated for about 63%of the people.However, the lower storage and transportation requirements of China will provide a new choice for the relatively backward regions where cold chain transportation.
Lugito also said that Indonesia plans to produce the vaccine in the local area.It is reported that Indonesia Tong Watson Biological has launched a localized production cooperation in Indonesia in Indonesia, and Watson Bio will help Indonesia to build its own regional vaccine production center.
On the other hand, Mainland China has not yet approved the use of any MRNA crown vaccine, and Watson Bio is still actively promoting the emergency authorization application of this vaccine in China.
